NNovo Nordisk Read More Novo Nordisk’s Pipeline Paradox: A $55 Billion Bet on Automation and a Quiet Drug Revolution2026-06-21 The market has handed Novo Nordisk a brutal 40% haircut over the past year, and the bears have…
GGreenland Read More Buybacks, Greenland, and a Cash-Rich Paradox2026-04-12 European Lithium launches a share buyback amid Greenland regulatory bottleneck for its Tanbreez rare earths project. The firm…